Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 2 , Pages 86-98 , April 2010

European perspectives on upcoming analgesics: What do they have that we don't—and what do they think about them?

  • Bart Morlion, MD

      Affiliations

    • Leuven Center for Algology and Pain Management, University Hospitals, Leuven, Belgium
    • ,
  • Joseph V. Pergolizzi Jr, MD

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland and Department of Anesthesiology, Georgetown University School of Medicine, Washington, District of Columbia
    • Corresponding Author InformationAddress reprint requests and correspondence: Joseph V. Pergolizzi Jr, MD, 840 111th Avenue North, Suite 7, Naples, FL 34108
    • ,
  • Robert B. Raffa, PhD

      Affiliations

    • Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania

References 

  1. International Association for the Study of Pain. Global year against musculoskeletal pain: October 2009–October 2010: Epidemiology of musculoskeletal pain. http://www.iasp-pain.org/AM/Template.cfm?Section=Fact_Sheets2&Template=/CM/ContentDisplay.cfm&ContentID=9280Accessed February 2, 2010
  2. World Health Organization. Supports global efforts to relieve pain, 2004. http://www.who.int/mediacentre/news/releases/2004/pr70/en/Accessed February 2, 2010
  3. Portenoy RK. Cancer pain epidemiology and symptoms. Cancer. 1989;63:2298–2307
  4. Lufty K, Eitan S, Bryant CD, et al. Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003;23:10331–10337
  5. Ide S, Minami M, Satoh M, et al. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in μ-receptor knockout mice. Neuropscyhopharmacology. 2004;29:1656–1663
  6. Cowan A, Lewis JW. Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York, NY: Wiley-Liss; 1995;
  7. Budd K, Raffa RB. Buprenorphine-the Unique Opioid Analgesic: Pharmacology and Clinical Application. New York, NY: Thieme; 2005;
  8. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297:688–695
  9. Traynor JR, Nahorski SR. Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1995;47:848–854
  10. Selley DE, Liu Q, Childers SR. Signal transduction correlates of mu opioid agonist intrinsic efficacy: Receptor-stimulated [35S]GTPγS binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther. 1998;285:496–505
  11. Toll L, Berzetei-Gurske IP, Polgar WE, et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 1998;178:440–466Available at: http://www.drugabuse.gov/pdf/monographs/178toc.pdf. Accessed February 2, 2010
  12. Lee KO, Akil H, Woods JH, Traynor JR. Differential binding properties of oripavines at cloned μ and δ-opioid receptors. Eur J Pharmacol. 1999;387:323–330
  13. Romero DV, Partilla JS, Zheng QX, et al. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective μ/κ antagonist in the [35S]-GTP-γ-S functional binding assay. Synapse. 1999;34:83–94
  14. Zhu J, Luo LY, Li JG, et al. Activation of the cloned human kappa Opioid receptor by agonists enhances [35S]GTPγS binding to membranes: Determination of potencies and efficacies of ligands. J Pharmacol Exp Ther. 1997;282:676–684
  15. Wnendt S, Krüger T, Janocha E, et al. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol. 1999;56:334–338
  16. Hashimoto Y, Calo G, Guerrini R, et al. Antagonistic effects of [Nphe1]nociceptin(1-13)NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese ovary hamster cells stably expressing the recombinant human nociceptin receptor. Neurosci Lett. 2000;278:109–112
  17. Hawkinson JE, Acosta-Burruel M, Espitia SA. Opioid activity profiles indicate similarities between the nociceptin/orphaning FQ and opioid receptors. Eur J Pharmacol. 2000;389:107–114
  18. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides. 2000;21:1141–1146
  19. Selley DE, Sim LJ, Xiao R, et al. μ-opioid receptor-stimulated guanosine-5′-O-(γ-thio)-triphosphate binding in rat thalamus and cultured cell lines: Signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol. 1997;51:87–96
  20. Greenwald MK, Johanson C, Moody DE, et al. Effects of buprenorphine maintenance dose of μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28:2000–2009
  21. Budd K, Collett BJ. Editorial III: Old dog—New (ma)Trix. J Anesth. 1981;36:900–903
  22. Raffa RB, Ding Z. Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. Acute Pain. 2007;9:145–152
  23. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94:825–834
  24. Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol. 2009;157:831–843
  25. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice—A post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005;21:1147–1156
  26. Landau CJ, Carr WD, Razzetti AJ, et al. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: A multicenter, 5-week run-in and randomized bule-blind maintenance-of-analgesia study. Clin Ther. 2007;29:2179–2193
  27. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26:1808–1820
  28. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25:150–168
  29. Karlsson M, Berggren A. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: A 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther. 2009;31:503–513
  30. Barutell C, Camba A, Gonzalez-Escalada J, et al. High dose transdermal buprenorphine for moderate to severe pain in Spanish pain centres—A retrospective multicenter safety and efficacy study. Pain Practice. 2008;8:355–361
  31. Penza P, Campanella A, Martini A, et al. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies. J Periph Nerv System. 2008;13:283–288
  32. Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine: A randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Sympt Manag. 2008;36:117–125
  33. Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: Results of a retrospective cohort study. Clin Ther. 2005;27:1022–1031
  34. Likar R, Vadlau EM, Breschan C, et al. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin J Pain. 2008;24:536–543
  35. Gallagher AM, Leighton-Scott J, van Staa TJ. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: A retrospective cohort study. Clin Ther. 2009;31:1707–1715
  36. Likar R, Lorenz V, Korak-Leiter M, et al. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: A single-site, phase III, randomized, open-label, crossover comparison. Clin Ther. 2007;29:1591–1606
  37. Raffa RB, Pergolizzi JV. Analgesic peroxide oil (essential oxygen oil): Postulated mechanism(s) of action against acute and chronic pain. J Clin Pharm Ther. 2010;(in press)
  38. Naik AK, Tandan SK, Dudhgaonkar SP, et al. Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-L-cysteine in rats. Eur J Pain. 2006;10:573–579
  39. Raghavendra V, Tanga F, Rutkowski MD, et al. Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: Mechanistic implications of spinal glia and proinflammatory cytokines. Pain. 2003;104:655–664
  40. Lima JA, Oliveira AS, de Miranda ALP, et al. Anti-inflammatory and antinociceptive activities of an acid fraction of the seeds of Carpotroche brasiliensis (Raddi) (Flacourtiaceae). Braz J Med Biol Res. 2005;38:1095–1103
  41. Zakaria ZA, Kumar GH, Mat Jais AM, et al. Antinociceptive, anti-inflammatory and antipyretic properties of Channa striatus fillet aqueous and lipid-based extracts in rats. Methods Find Exp Clin Pharmacol. 2008;30:355–362
  42. Winter CA, Risely EA, Nuss GW. Carregenin induced oedema in hind paw of the rats as an assay of anti-inflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544–547
  43. Singh S, Majumdar DK, Yadav MR. Chemical and pharmacological studies on fixed oil of Ocimum sanctum. Ind J Exp Biol. 1996;34:1212–1215
  44. Chen YF, Li N, Jiao YL, et al. Antinociceptive activity of petroleum ether fraction from the MeOH extracts of Paederia scandens in mice. Phytomedicine. 2008;15:427–436
  45. Zakaria ZA, Sulaiman MR, Mat Jais AM, et al. Effect of various antagonists of the Channa striatus fillet extract antinociception in mice. Can J Physiol Pharmacol. 2005;83:635–642
  46. Dambisya YM, Lee TL, Sathivulu V, et al. Influence of temperature, pH and naoloxone on the antinociceptive activity of Channa striatus (haruan) extracts in mice. J Ethnopharmacol. 1999;66:181–186
  47. Pergolizzi JV, Pappagallo M, Raffa RB, et al. Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromes. 2010;(in press)
  48. Tzschenktke TM, Christoph T, Kögel B, et al. (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265–276
  49. Raffa RB, Friderichs E. The basic science aspect of tramadol hydrochloride. Pain Rev. 1996;3:249–271
  50. Raffa RB, Friderichs E, Reiman W, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1993;267:331–340
  51. Wu WN, McKown LA, Gauthier AD, et al. Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog. Xenobiotica. 2001;31:423–441
  52. Terlinden R, Ossig J, Fliegert F, et al. Pharmacokinetics, excretion, and metabolism of tapentadol HCl, a novel centrally acting analgesic, in healthy subjects [abstract]. J Pain. 2006;7(suppl 2):S26
  53. Terlinden R, Ossig J, Fliegert F, et al. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Durg Metab Pharmacokinet. 2007;32:163–169
  54. Nager S, Raffa RB. Looking beyond the administered drug: Metabolites of opioid analgesics. J Fam Pract. 2008;57(suppl):S25–S32
  55. Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009;31:260–271
  56. Daniels SE, Upmalis D, Okamoto A, et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009;25:765–776
  57. Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double-blind study. Curr Med Res Opin. 2009;25:1095–1104
  58. Stegmann JU, Weber H, Steup A, et al. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin. 2008;24:3185–3196
  59. Hartrick CT. Tapentadol immediate release for the relief of moderate to severe acute pain. Exp Opin Pharmacol Ther. 2009;10:2687–2696
  60. Kleinert R, Lange C, Steup A, et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: The results of a randomized, double-blind, placebo-controlled stuy. Anesth Analg. 2008;107:2048–2055
  61. Klein T, Nüsing RM, Pfeilschifter J, et al. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol. 1994;18:1605–1610
  62. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivites for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA. 1994;90:11693–11697
  63. Riendeau D, Charleston S, Cromlish W, et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsterioidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol. 1997;75:1088–1095
  64. Blanco FJ, Guitian R, Moreno J, et al. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999;26:1366–1373
  65. Giuliano F, Warner TD. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol. 1999;126:1824–1830
  66. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:413–421
  67. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109–1120
  68. Björkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol (Experimental studies in the rate). Acta Anaesthesiol Scand Suppl. 1995;103:1–44
  69. Buritova J, Honore P, Chapman V, et al. Concurrent reduction of inflammation and spinal Fos-LI neurons by systemic diclofenac in the rate. Neurosci Lett. 1995;188:175–178
  70. Masue T, Dohi S, Asano T, et al. Spinal antinociceptive effect of epidural nonsteroidal anti-inflammatory drugs on nitric oxide-induced hyperalgesia in rats. Anesthesiology. 1999;91:198–206
  71. Ortiz MI, Lozano-Cuenca J, Grandados-Soto V, et al. Additive interaction between peripheral and central mechanisms involved in the antinociceptive effect of diclofenac in the formalin test in rats. Pharmacol Biochem Behav. 2008;91:32–37
  72. Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab. 2003;4:319–329
  73. Joint meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and Anesthetic and Life Support Drugs Committee; notice of meeting. Fed Regist. 2009;74;http://www.fda.gov/OHRMS/DOCKETS/98fr/E9-9380.pdfAccessed May 26, 2009
  74. Mibielli MA, Geller M, Cohen JC, et al. Diclofenac plus B vitamins versus diclofenac mnotherapy in lumbago: The DOLOR study. Curr Med Res Opin. 2009;25:2589–2599
  75. Iacovides S, Avidon I, Bentley A, et al. Diclofenac potassium restores objective and subjective measures of sleep quality in women with primary dysmenorrheal. Sleep. 2009;32:1019–1026
  76. Barthel HR, Haselwood D, Longley S, et al. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arhtritis Rheum. 2009;39:203–212
  77. Senol A, Saritas U, Demirkan H. Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol. 2009;15:3999–4004
  78. Wagh MS, Sherman S. Indomethacin for post-ERCP pancreatitis prophylasix: Another attempt at the Holy Grail. Am J Gastroenterol. 2007;102:984–986
  79. Standing JF, Ooi K, Keady S, et al. Prospective observational study of adverse drug reactions to diclofenac in children. Br J Clin Pharmacol. 2009;68:243–251
  80. Altman RD, Dreiser RL, Fisher CL. Diclofenac sodium gel in patients with primary hand osteoarthritis: A randomized, double-blind, placebo-controlled trial. J Rheumtaol. 2009;36:1991–1999
  81. Surakarn J, Tannirandorn Y. Intramuscular diclofeanc for analgesia after Cesarean delivery: A randomized controlled trial. J Med Assoc Thai. 2009;92:733–738
  82. Eryildirim B, Kuyumcuoglu U, Tarhan F, et al. Comparison of three analgesic treatment protocols for pain management during extracorporeal shock wave lithotripsy. Urol Int. 2009;82:276–279

PII: S1084-208X(10)00019-4

doi: 10.1053/j.trap.2010.03.002

Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 2 , Pages 86-98 , April 2010

Article Tools

* Image Usage & Resolution